The products of the nonenzymatic glycation and oxidation of proteins, lipids and nucleic acids, the advanced glycation end-products (AGEs), accumulate in various pathological conditions, such as diabetes, inflammation, renal failure, and aging. AGEs accumulate at site of microvascular injury in diabetes, including the kidney, the retina, and within the vasculature. The enhanced formation of AGEs also exists in various disease, such as atherosclerosis, Alzheimer’s disease, end-stage renal disease (ESRD), rheumatoid arthritis and liver cirrhosis.
AGEs can arise not only from glucose, but also from dicarbonyl compounds, short chain-reducing sugars and other metabolic pathways of glucose. It has been showed that glucose-derived AGEs (named AGE-1) causes apoptotic cell death and induces hyperfiltration and microalbuminuria by stimulating secretion of VEGF and MCP-1 proteins in the human mesangial cells. Therefore, AGE-1 may be involved in the pathogenesis of the early stage of diabetic nephropathy.
This antibody is specific to AGE-1 and will be useful to research for diabetes, complications of diabetes.
To be used for research only. DO NOT use for human gene therapy or clinical diagnosis.